Close
FINDING CURES TOGETHER<sup>SM</sup>

AACR Annual Meeting 2017

The following changes were made to the program after April 4, 2017. These changes have been made in the online and app versions of the program. 


Monday, April 3, 2017

Meet-the-Expert Session: Regulation of Immune Cell Function and Spatiality by Diverse Stromal Niches
Monday, April 3, 2017, 7:00 a.m.-8:00 a.m.
Room 207, Level 2, Washington Convention Center

Dr. Viviana Cremasco, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, will replace Dr. Shannon J. Turley, Genentech, Inc., South San Francisco, California. Dr. Cremasco's title is: "Regulation of Immune Cell Function and Spatiality by Diverse Stromal Niches".


Minisymposium Session: Identification of Molecular Targets
Monday, April 3, 2017, 3:00 p.m.-5:00 p.m.
Room 147, Level 1, Washington Convention Center

Dr. Timothy L. Chen, The Ohio State University, Columbus, Ohio, will replace Dr. Erin Hertlein, The Ohio State University, Columbus, Ohio. Dr. Chen's title is: "BCL3 over-expression contributes an in vivo growth advantage in a B-cell lymphoma xenograft model and is a risk factor for ibrutinib relapse in CLL".


Tuesday, April 4, 2017

SU2C Innovative Research Grant Poster Session
Tuesday, April 4, 2017, 10:30 a.m.-12:30 p.m.
Marquis Ballroom Salons 1-2, Meeting Level 2, Marriott Marquis DC

This session has been canceled.


Precision Medicine: Will It Be of Benefit in Pediatric Cancer Patients?
Tuesday, April 4, 2017, 5:00 pm - 6:30 pm
Room 150, Level 1, Washington Convention Center

Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, Massachusetts, will replace John M. Maris, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, as Moderator of the session.


Nanotechnology for Cancer Diagnosis and Therapy
Tuesday, April 4, 2017, 1:00 p.m.-2:45 p.m.
Room 150, Level 1, Washington Convention Center

Dr. Mustafa Diken, TRON Institute for Translational Oncology, Mainz, Germany, will replace Dr. Ugur Sahin, BioNTech AG, Mainz, Germany, as the Chair and a presenter in this session.  


Wednesday, April 5, 2017

The Emerging Role of lncRNAs in Cancer Biology
Wednesday, April 5, 2017, 7:00 a.m.-8:00 a.m.
Room 206, Level 2, Washington Convention Center

Dr. Jean-Christophe W. Marine, VIB Center for Cancer Biology, Leuven, Belgium, has canceled his talk. 


Saturday, April 1, 2017

Resistance Mechanisms to MAPK Pathway Targeting Across Cancer
Saturday, April 1, 2017, 8:00 a.m.-10:00 a.m.
Room 201, Level 2, Washington Convention Center
Chair: Roger S. Lo. UCLA, Los Angeles, California

Speaker times have changed and titles have been provided.

Mechanisms of resistance to MAPK pathway inhibition in melanoma
8:00 a.m.
Willy Hugo, UCLA, Los Angeles, California

Overcoming heterogeneity and resistance to MAPK inhibition 
9:00 a.m.
Ryan B. Corcoran, Massachusetts General Hospital Cancer Center, Boston, Massachusetts


Clinical Trials Design Workshop - Part 1: Clinical Trials for Targeted Therapies

Saturday, April 1, 2017, 8:00 a.m.-10:00 a.m.
Room 145, Level 1, Washington Convention Center

Dr. Siraj M. Ali will replace Dr. Vincent A. Miller. Dr. Ali's title is: "Update of biomarker prevalence identified by next generation sequencing".


Cancer Immunology for the Non-Immunologist: Tutorial
Saturday, April 1, 2017, 10:15 a.m.-12:15 p.m.
Independence Ballroom E-H, Meeting Level 4, Marriott Marquis DC

Dr. Charles G. Drake’s title has been updated: “Immunotherapy in GU cancers”.


Computational Analysis of Cancer
Saturday, April 1, 2017, 10:15 a.m.-12:15 p.m.
Room 202, Level 2, Washington Convention Center

Dr. Chip Stewart will replace Dr. Gad Getz as chair and speaker. Dr. Stewart's title will be; "Discovery of cancer genes".


Integrating Genomic Analyses of Immunotherapy
Saturday, April 1, 2017, 10:15 a.m.-12:15 p.m.
Ballroom A-B, Level 3, Washington Convention Center

Dr. Valsamo Anagnostou will replace Dr. Victor Velculescu. Dr. Anagnostou's title will be; "Dynamics of genomic and neoantigen landscape during immune checkpoint blockade".


Top of page


Robustness: Enhancing Research Reproducibility
Saturday, April 1, 2017, 10:15 a.m.-12:15 p.m.
Room 144, Level 1, Washington Convention Center

Speaker times have changed and titles have been provided.

Introduction
10:15 a.m.
Jeremy Berg, Science/AAAS, Washington, D.C.

Robustness: Enhancing research reproducibility
10:55 a.m.
Chi Van Dang, Abramson Cancer Center of University of Pennsylvania, Philadelphia, Pennsylvania

Enhancing research reproducibility: A view from NIH 
11:35 a.m.
Lawrence Tabak, National Institutes of Health, Bethesda, Maryland 


Clinical Trials Design Workshop - Part 2: Development of Immuno-Oncologic Treatments
Saturday, April 1, 2017, 10:15 a.m.-12:15 p.m.
Room 145, Level 1, Washington Convention Center

Speaker times have changed and Dr. Chapman's title has been updated.

Thoughts on modernizing clinical trial design for immunotherapy 
10:15 a.m.
Paul B. Chapman, Memorial Sloan Kettering Cancer Center, New York, New York

Clinical and diagnostic considerations for a personalized cancer immunotherapy paradigm
10:55 a.m.
Priti S. Hegde, Genentech, Inc., South San Francisco, California

Statistical challenges in evaluating immunologic treatments for cancer 
11:35 a.m.
Aparna Anderson, Statistics Collaborative, Inc., Washington, D.C.


Twentieth Annual Grant Writing Workshop, Organized by the Associate Member Council (AMC)
Saturday, April 1, 2017, 12:00 p.m.-5:00 p.m.
Constitution Ballroom A-B, Level 3B, Grand Hyatt Washington

Dr. Jean J. Zhao, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, will not be participating as a roundtable mentor.


From Chemistry to the Clinic: Part 3: Advances in Antibody Drug Conjugates
Saturday, April 1, 2017, 1:00 p.m.-3:00 p.m.
Room 147, Level 1, Washington Convention Center

Speaker times have changed.

Enabling the next generation of calicheamicin-based antibody-drug conjugates 
1:00 p.m.
Russell G. Dushin, Pfizer, Inc., Groton, Connecticut 

Influence of payload physiochemical properties and linker structure on antibody-drug conjugate activity 
1:40 p.m.
Peter S. Dragovich, Genentech, Inc., South San Francisco, California

Expanding the payload scope and drug load of ADCs through drug-linker design 
2:20 p.m.
Patrick J. Burke, Seattle Genetics, Inc., Bothell, Washington


Targeting CDKs in the Treatment of Breast Cancers
Saturday, April 1, 2017, 1:00 p.m.-3:00 p.m.
Room 145, Level 1, Washington Convention Center

Dr. Jean J. Zhao, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, has canceled her talk "CDKs beyond the cell cycle".

Rationale and Design of Immune Checkpoint Combination Therapy
Saturday, April 1, 2017, 1:00 p.m.-3:00 p.m.
Ballroom A-B, Level 3, Washington Convention Center

Dr. Marc Theoret’s title has been updated: “Special regulatory considerations for the development of immune combination trials”.


Translation Control in Cancer: From Basic Science to Therapeutic Approaches
Saturday, April 1, 2017, 1:00 p.m.-3:00 p.m.
Room 206, Level 2, Washington Convention Center

The times of Drs. Sonenberg's and Ruggero's talks have changed.

The role of eIF4E in cancer metastasis
1:00 p.m.
Nahum Sonenberg, McGill University, Montreal, Quebec, Canada

Translating the cancer genome one codon at a time and its therapeutic implications 
1:25 p.m.
Davide Ruggero, The University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California


Top of page


Methods to Investigate the Microbiota
Saturday, April 1, 2017, 1:00 p.m. - 3:00 p.m.
Room 144, Level 1, Washington Convention Center
Chair: Laurence Zitvogel, Gustave Roussy Cancer Center, Villejuif, France

Speakers, talk times, and titles have been updated.

Functional profiling and integration of metagenomes, metatranscriptomes, and metabolomes 
1:00 p.m.
Curtis Huttenhower, Harvard T.H. Chan School of Public Health, Boston, Massachusetts  

High-resolution microbiome profiling with implications for cancer research 
1:30 p.m.
James R. White, Resphera Biosciences, Baltimore, Maryland

Title to be announced
2:00 p.m.
Vancheswaran Gopalakrishnan, The University of Texas MD Anderson Cancer Center, Houston, Texas

Dissecting microbiota function using germ-free vertebrate model systems: Significance for cancer research
2:30 p.m.
Christian Jobin, University of Florida, Gainesville, Florida


Inflammation and Immune Cells as Modifiers of Outcome in Cancer Patients

Saturday, April 1, 2017, 3:15 p.m.-5:15 p.m.
Room 146, Level 1, Washington Convention Center

Dr. Jerome Galon’s title has been updated: “Pre-existing immunity and immunoscore are major determinant of cancer patient survival”.

Dr. Luis A. Diaz's title has been updated: "Genetic determinants of immunogenicity and response to therapy".


Targeting the Tumor Microenvironment Through Small Molecule Drugs
Saturday, April 1, 2017, 3:15 p.m.-5:15 p.m.
Ballroom A-B, Level 3, Washington Convention Center
Chair: Axel Hoos, GlaxoSmithKline, Collegeville, Pennsylvania

Speaker order has changed.

Introduction
Axel Hoos

Designing small molecule drugs for modulating the tumor microenvironment
3:15 p.m.
Jingsong Yang. GlaxoSmithKline, Collegeville, Pennsylvania

Reprogramming tumor associated macrophages by targeting PI3K-gamma through a small molecule approach
3:55 p.m.
Jeffery Kutok, Infinity Pharmaceuticals, Cambridge, Massachusetts

Adenosine antagonists for cancer immunotherapy
4:35 p.m.
Ian McCaffery, Corvus Pharmaceuticals Inc,, Burlingame, California


Dissemination and Implementation Research
Saturday, April 1, 2017, 3:15 p.m.-5:15 p.m.
Room 204, Level 2, Washington Convention Center
Chair: David A. Chambers, National Cancer Institute, Rockville, Maryland 

Full session information has been updated.

An introduction to dissemination and implementation research: Rationale, progress, and futuredirections
3:15 p.m.
David A. Chambers, National Cancer Institute, Rockville, Maryland

Research methods, designs, and outcomes in implementation science
3:55 p.m.
Wynne Norton, National Cancer Institute, Rockville, Maryland

Conducting dissemination and implementation research: Perspectives from the field
4:35 p.m.
Electra D. Paskett, Ohio State University Comprehensive Cancer Center, Columbus, Ohio


Unsolved Mysteries: Why Is Pancreatic Cancer So Difficult to Treat?
Saturday, April 1, 2017, 5:15 p.m. - 6:45 p.m.
Room 202, Level 2, Washington Convention Center

Dr. Margaret A. Tempero, UCSF, San Francisco, California, has canceled her talk "A beginner’s guide to perplexing clinical issues in pancreatic adenocarcinoma". She will be replaced by Dr. Jordan D. Berlin, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.


Sunday, April 2, 2017

Clinical Trials Plenary Session: Precision Medicine Clinical Trials
Sunday, April 2, 2017, 12:45 p.m.-3:00 p.m.
Ballroom C, Level 3, Washington Convention Center

Dr. Salvatore Siena, Grande Ospedale Metropolitano Niguarda, Milano, Italy, has canceled his talk "Final results of the HERACLES trial in HER2-amplified colorectal cancer". He will be replaced by Silvia Marsoni, Fondazione Piemonte Per L'Oncolgia, Candiolo (Torino), Italy.


Breast Cancer, Ovarian Cancer, and Glioblastoma Clinical Trials
Sunday, April 2, 2017, 3:00 p.m.-5:00 p.m.
Ballroom C, Level 3, Washington Convention Center

Jame Abraham, NSABP and the Cleveland Clinic, Cleveland, Ohio, will replace Samuel Jacobs, NSABP, Pittsburgh, Pennsylvania. The title of Dr. Abraham's talk is "V NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DMI) with neratinib (N) in women with metastatic HER2+ breast cancer (MBC)".


Wednesday, April 5, 2017

Meet-the-Expert Session: Progression of Premalignant Lesions
Wednesday, April 5, 2017, 7:00 a.m.-8:00 a.m.
East Salon C, Level 1, Washington Convention Center

This session title has changed to, "Interplay of Infection and Somatic Genomic Alterations in Cancer".

Top of page